Incyte Stock Forecast, Price & News

Incyte (NASDAQ:INCY) Frequently Asked Questions

Is Incyte a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 1 sell rating, 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Incyte stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View analyst ratings for Incyte or view top-rated stocks.

What stocks does MarketBeat like better than Incyte?

Wall Street analysts have given Incyte a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Incyte wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Incyte's next earnings date?

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Incyte.

How can I listen to Incyte's earnings call?

Incyte will be holding an earnings conference call on Tuesday, November 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13724199".

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) posted its earnings results on Tuesday, August, 3rd. The biopharmaceutical company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.54 by $0.26. The biopharmaceutical company had revenue of $705.71 million for the quarter, compared to analyst estimates of $686.95 million. Incyte had a net margin of 12.41% and a trailing twelve-month return on equity of 15.77%. The business's revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.24 EPS.
View Incyte's earnings history.

How has Incyte's stock been impacted by Coronavirus (COVID-19)?

Incyte's stock was trading at $71.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INCY shares have decreased by 8.4% and is now trading at $65.87.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for INCY?

11 Wall Street analysts have issued 1 year target prices for Incyte's stock. Their forecasts range from $67.00 to $124.00. On average, they anticipate Incyte's share price to reach $89.11 in the next year. This suggests a possible upside of 35.3% from the stock's current price.
View analysts' price targets for Incyte or view top-rated stocks among Wall Street analysts.

Who are Incyte's key executives?

Incyte's management team includes the following people:

• Herve Hoppenot, Chairman, President & Chief Executive Officer
• Christiana Stamoulis, Chief Financial Officer & Executive Vice President
• Steven H. Stein, Chief Medical Officer & Executive Vice President
• Dashyant Dhanak, Chief Scientific Officer & Executive VP (LinkedIn Profile)
• Barry Flannelly, Executive Vice President & General Manager

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte CEO Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among Incyte's employees.

Who are some of Incyte's key competitors?

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Repligen (RGEN), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of INCY's competitors.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Virginia Retirement Systems ET AL (0.13%), Chevy Chase Trust Holdings Inc. (0.05%), Nisa Investment Advisors LLC (0.04%), Exchange Traded Concepts LLC (0.02%), Robeco Institutional Asset Management B.V. (0.01%) and State of Alaska Department of Revenue (0.01%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Michael James Morrissey, Paul Trower, Paula J Swain, Steven H Stein, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends for Incyte.

Which major investors are selling Incyte stock?

INCY stock was sold by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Chevy Chase Trust Holdings Inc., Assenagon Asset Management S.A., Tributary Capital Management LLC, Veriti Management LLC, Robeco Institutional Asset Management B.V., State of Alaska Department of Revenue, and New Mexico Educational Retirement Board. Company insiders that have sold Incyte company stock in the last year include Dashyant Dhanak, Michael James Morrissey, Vijay K Iyengar, and Yao Wenqing.
View insider buying and selling activity for Incyte or view top insider-selling stocks.

Which major investors are buying Incyte stock?

INCY stock was bought by a variety of institutional investors in the last quarter, including Virginia Retirement Systems ET AL, Searle & CO., Everence Capital Management Inc., North Star Asset Management Inc., Exchange Traded Concepts LLC, Pacer Advisors Inc., Fifth Third Bancorp, and Nisa Investment Advisors LLC. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, and Herve Hoppenot.
View insider buying and selling activity for Incyte or or view top insider-buying stocks.

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $65.87.

How much money does Incyte make?

Incyte has a market capitalization of $14.55 billion and generates $2.67 billion in revenue each year. The biopharmaceutical company earns $-295.70 million in net income (profit) each year or ($1.06) on an earnings per share basis.

How many employees does Incyte have?

Incyte employs 1,773 workers across the globe.

When was Incyte founded?

Incyte was founded in 1991.

What is Incyte's official website?

The official website for Incyte is www.incyte.com.

Where are Incyte's headquarters?

Incyte is headquartered at 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at (302) 498-6700 or via email at [email protected].